Please inform of the many front line treatments for 1+, 2+. Thanks. Progress in this area of an unmet need is being seen by AstraZeneca and Daiichi Sankyo in the DESTINY-Breast01 study. And if one part of 4 isn’t acknowledged as being less than the full 4 (AE original appraisal) then I’m nuts. No one is saying it’s not an important and potentially highly lucrative market.